文献速递核素与放射性配体治疗

一种新型177Lu标记、具有去免疫化ABD结构域且生物分布改善的治疗性Affibody分子的评估

Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-07-15

本研究将靶向HER2的Affibody分子ZHER2:2891与去免疫化ABD变体融合并经DOTA偶联,制备新型探针PEP49989,用177Lu标记后表征其亲和力、特异性及体内靶向特性,并在人HER2表达异种移植瘤小鼠中评估实验性治疗。结果显示[177Lu]Lu-PEP49989具有特异性HER2结合,肾脏摄取较[177Lu]Lu-ABY-027高1.4倍而肝脾摄取低1.7-2倍,21 MBq治疗组中位生存期超过90天、显著长于溶媒组38天和曲妥珠单抗组45天,联合曲妥珠单抗增加完全缓解数,肾肝毒性轻微。

要点

  • 新型去免疫化ABD融合Affibody分子[177Lu]Lu-PEP49989最高摩尔活度为52 GBq/µmol。
  • 肾脏摄取较[177Lu]Lu-ABY-027高1.4倍,肝脾摄取低1.7-2倍。
  • 21 MBq治疗组中位生存期超过90天,显著长于溶媒组38天和曲妥珠单抗组45天。

核心结论

  • 在临床前研究中,[177Lu]Lu-PEP49989表现出有利的生物分布和强抗肿瘤效应,与曲妥珠单抗联合治疗可进一步增强该效应。

研究设计与样本

  • 将靶向HER2的Affibody分子ZHER2:2891与去免疫化ABD变体融合,经DOTA偶联于独特C端半胱氨酸构建新型分子PEP49989,并用177Lu标记。
  • 表征[177Lu]Lu-PEP49989的亲和力、特异性及体内靶向特性,并在人HER2表达异种移植瘤小鼠中评估实验性治疗。

主要发现

  • [177Lu]Lu-PEP49989最高摩尔活度为52 GBq/µmol。
  • [177Lu]Lu-PEP49989在体外和体内均特异性结合HER2表达细胞,其HER2结合亲和力与含亲本ABD035变体的[177Lu]Lu-ABY-027相似。
  • [177Lu]Lu-PEP49989肾脏摄取较[177Lu]Lu-ABY-027高1.4倍,肝脏和脾脏摄取较[177Lu]Lu-ABY-027低1.7-2倍。
  • 接受21 MBq [177Lu]Lu-PEP49989治疗的异种移植瘤小鼠中位生存期超过90天,显著长于溶媒组38天和曲妥珠单抗组45天。
  • [177Lu]Lu-PEP49989与曲妥珠单抗联合治疗增加完全肿瘤缓解数,肾和肝毒性为轻微至轻度。

关键数值与推荐

  • [177Lu]Lu-PEP49989最高摩尔活度为52 GBq/µmol。
  • 21 MBq [177Lu]Lu-PEP49989治疗组小鼠中位生存期超过90天,溶媒组为38天,曲妥珠单抗组为45天。
  • [177Lu]Lu-PEP49989肾脏摄取较[177Lu]Lu-ABY-027高1.4倍,肝脏和脾脏摄取较[177Lu]Lu-ABY-027低1.7-2倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fusion of Affibody molecules with an albumin-binding domain (ABD) provides targeting agents, which are suitable for radionuclide therapy. To facilitate clinical translation, the low immunogenic potential of such constructs with targeting properties conserved is required. METHODS: The HER2-targeting Affibody molecule ZHER2:2891 was fused with a deimmunized ABD variant and DOTA was conjugated to a unique C-terminal cysteine. The novel construct, PEP49989, was labelled with 177Lu. Affinity, specificity, and in vivo targeting properties of [177Lu]Lu-PEP49989 were characterised. Experimental therapy in mice with human HER2-expressing xenografts was evaluated. RESULTS: The maximum molar activity of 52 GBq/µmol [177Lu]Lu-PEP49989 was obtained. [177Lu]Lu-PEP49989 bound specifically to HER2-expressing cells in vitro and in vivo. The HER2 binding affinity of [177Lu]Lu-PEP49989 was similar to the affinity of [177Lu]Lu-ABY-027 containing the parental ABD035 variant. The renal uptake of [177Lu]Lu-PEP49989 was 1.4-fold higher, but hepatic and splenic uptake was 1.7-2-fold lower than the uptake of [177Lu]Lu-ABY-027. The median survival of xenograft-bearing mice treated with 21 MBq [177Lu]Lu-PEP49989 (> 90 days) was significantly longer than the survival of mice treated with vehicle (38 days) or trastuzumab (45 days). Treatment using a combination of [177Lu]Lu-PEP49989 and trastuzumab increased the number of complete tumour remissions. The renal and hepatic toxicity was minimal to mild. CONCLUSION: In preclinical studies, [177Lu]Lu-PEP49989 demonstrated favourable biodistribution and a strong antitumour effect, which was further enhanced by co-treatment with trastuzumab.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu Y, Oroujeni M, Liao Y, et al. Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile. Eur J Nucl Med Mol Imaging. 2024. PMID: 39008065. doi:10.1007/s00259-024-06840-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。